Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

LoKara

&times

Overview

What is LoKara?

LoKara Lotion (desonide lotion 0.05%) contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (11β,16α-) a synthetic nonfluorinated corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primarily synthetic steroids used topically as anti-inflammatory and anti-pruritic agents.

Chemically, desonide is CHO. It has the following structural formula:

Desonide has the molecular weight of 416.51. It is a white to off white odorless powder which is soluble in methanol and practically insoluble in water.

Each gram of LoKara Lotion (desonide lotion 0.05%) contains 0.5 mg of desonide in a base of sodium lauryl sulfate, light mineral oil, cetyl alcohol, stearyl alcohol, propylene glycol, methylparaben, propylparaben, sorbitan monostearate, glyceryl stearate SE, edetate sodium, citric acid anhydrous and purified water. May also contain additional citric acid and/or sodium hydroxide for pH adjustment.



What does LoKara look like?



What are the available doses of LoKara?

Sorry No records found.

What should I talk to my health care provider before I take LoKara?

Sorry No records found

How should I use LoKara?

LoKara Lotion (desonide lotion 0.05%) is a low to medium potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses.

LoKara Lotion (desonide lotion 0.05%) should be applied to the affected areas as a thin film two or three times daily depending on the severity of the condition.

SHAKE WELL BEFORE USING.

As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.

LoKara Lotion (desonide lotion 0.05%) should not be used with occlusive dressings.


What interacts with LoKara?

Sorry No Records found


What are the warnings of LoKara?

Sorry No Records found


What are the precautions of LoKara?

Sorry No Records found


What are the side effects of LoKara?

In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide was approximately 8%. These were: stinging and burning approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, itching, intense transient erythema, and dryness/scaliness, each less than 2%.

The following additional local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.


What should I look out for while using LoKara?

LoKara Lotion (desonide lotion 0.05%) is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.


What might happen if I take too much LoKara?

Topically applied LoKara Lotion (desonide lotion 0.05%) can be absorbed in sufficient amounts to produce systemic effects (see ).


How should I store and handle LoKara?

Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733Store at controlled room temperature 20°-25°C (68°-77°F). [See USP.]Dispense in light-resistant containers.Metformin hydrochloride extended-release tablets, USP are manufactured by:Watson Laboratories, Inc.Corona, CA 92880 USADistributed by:Watson Pharma, Inc.Marketed/Packaged by: GSMS Inc. Camarillo, CA 93012Rev. date 05/09                                                                         190733LoKara Lotion (desonide lotion 0.05%) is supplied in bottles as follows: 59 mL (2 fl oz) NDC 0462-0392-02118 mL (4 fl oz) NDC 0462-0392-04 Store between 2° and 30°C (36° and 86°F). PharmaDerma division of ALTANA IncI8392B/IF8392BR3/06#118 LoKara Lotion (desonide lotion 0.05%) is supplied in bottles as follows: 59 mL (2 fl oz) NDC 0462-0392-02118 mL (4 fl oz) NDC 0462-0392-04 Store between 2° and 30°C (36° and 86°F). PharmaDerma division of ALTANA IncI8392B/IF8392BR3/06#118 LoKara Lotion (desonide lotion 0.05%) is supplied in bottles as follows: 59 mL (2 fl oz) NDC 0462-0392-02118 mL (4 fl oz) NDC 0462-0392-04 Store between 2° and 30°C (36° and 86°F). PharmaDerma division of ALTANA IncI8392B/IF8392BR3/06#118 LoKara Lotion (desonide lotion 0.05%) is supplied in bottles as follows: 59 mL (2 fl oz) NDC 0462-0392-02118 mL (4 fl oz) NDC 0462-0392-04 Store between 2° and 30°C (36° and 86°F). PharmaDerma division of ALTANA IncI8392B/IF8392BR3/06#118 LoKara Lotion (desonide lotion 0.05%) is supplied in bottles as follows: 59 mL (2 fl oz) NDC 0462-0392-02118 mL (4 fl oz) NDC 0462-0392-04 Store between 2° and 30°C (36° and 86°F). PharmaDerma division of ALTANA IncI8392B/IF8392BR3/06#118 LoKara Lotion (desonide lotion 0.05%) is supplied in bottles as follows: 59 mL (2 fl oz) NDC 0462-0392-02118 mL (4 fl oz) NDC 0462-0392-04 Store between 2° and 30°C (36° and 86°F). PharmaDerma division of ALTANA IncI8392B/IF8392BR3/06#118


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Like other topical corticosteroids, desonide has anti-inflammatory, antipruritic and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However corticosteroids are thought to act by the induction of phospholipase A inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A.

Non-Clinical Toxicology
LoKara Lotion (desonide lotion 0.05%) is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

General:

Patients applying a topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using the ACTH stimulation, A.M. plasma cortisol, and urinary free cortisol tests. Patients receiving superpotent corticosteroids should not be treated for more than 2 weeks at a time and only small areas should be treated at any one time due to the increased risk of HPA axis suppression.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.

Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (See ).

If irritation develops, LoKara Lotion (desonide lotion 0.05%) should be discontinued and appropriate therapy instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.

If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of LoKara Lotion (desonide lotion 0.05%) should be discontinued until the infection has been adequately controlled.

In controlled clinical trials, the total incidence of adverse reactions associated with the use of desonide was approximately 8%. These were: stinging and burning approximately 3%, irritation, contact dermatitis, condition worsened, peeling of skin, itching, intense transient erythema, and dryness/scaliness, each less than 2%.

The following additional local adverse reactions have been reported infrequently with other topical corticosteroids, and they may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids. These reactions are listed in an approximate decreasing order of occurrence: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).